Blueprint Medicines’ Promising Pipeline Developments Support Buy Rating
Analyst Ami Fadia of Needham maintained a Buy rating on Blueprint Medicines (BPMC – Research Report), retaining the price target of ...
Medscape1h
FDA Considers New Dupilumab Data for Chronic Spontaneous Urticaria Indication
The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for ...
Monthly Prescribing Reference3d
FDA to Review Resubmitted Dupilumab sBLA for Chronic Spontaneous Urticaria
for the treatment of chronic spontaneous urticaria (CSU) in adults and pediatric patients aged 12 years and older inadequately controlled with H1 antihistamine treatment. The original sBLA was ...
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...
manilatimes6d
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...
Medscape6d
Classification and Treatment of Urticaria: A Brief Review
It is also good practice to recommend avoiding codeine and other opiates in view of the enhanced skin test reactions to codeine found in chronic urticaria. The role of avoiding dietary ...
ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive ...
GlobalData on MSN3d
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.